China's Ministry Of Health To Expand Corruption Probe In Pharma Sector
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Investors in China-based pharmaceutical firms have been so rattled by a widening government probe into potentially improper payments to regulators and doctors, and by the review of drug price levels for possible state-mandated cuts, that they have begun selling off equity stakes in those firms, according to a prominent analyst who closely follows China's healthcare sector from Merrill Lynch's office in Hong Kong
You may also be interested in...
Hospital Bribery Continues In Asia Despite Increased Enforcement
HONG KONG - The use of bribery as a standard business practice in Asia remains a concern for pharma industry observers, despite the fact that more countries are actively enforcing international anti-bribery conventions
Hospital Bribery Continues In Asia Despite Increased Enforcement
HONG KONG - The use of bribery as a standard business practice in Asia remains a concern for pharma industry observers, despite the fact that more countries are actively enforcing international anti-bribery conventions
Return Of Anti-commercial Bribery Campaign In China Could Benefit Big Companies And Blacklist Others
SHANGHAI - Last month, China's Ministry of Health released a notice urging local health authorities to crack down on kickbacks to doctors in return for sales of pharmaceutical products under a policy that would ban drug manufacturers from participating in drug tenders in public hospitals for two years if they are blacklisted